截至12月29日收盘，PEEK材料概念上涨3.23%，位居概念板块涨幅第1，板块内，40股上涨，恒勃股份 20%涨停，超捷股份、光威复材、美好医疗等涨幅居前，分别上涨16.35%、14.86%、8.30%。跌幅居前 的有天赐材料、凯盛新材、中国巨石等，分别下跌3.80%、3.21%、3.01%。 PEEK材料概念资金流入榜 | | 代码 | 简称 | 今日涨跌幅 | 今日换手率 | 主力资金流量（万 | 主力资金净流入比率 | | --- | --- | --- | --- | --- | --- | --- | | | | | （%） | （%） | 元） | （%） | | 14.86 | 300699 材 | 光威复 | | 16.73 | 34802.32 | 6.42 | | 1.87 | 600143 技 | 金发科 | | 4.19 | 20805.21 | 9.93 | | 3.81 | 002850 | 科达利 | | 4.19 | 13969.70 | 10.81 | | 3.17 | 300100 份 | 双林股 | | 4.42 | 10580.03 | 11.17 | | 2.28 ...

Market Overview - The medical device sector experienced a decline of 0.74% on December 29, with Huakang Clean leading the drop [1] - The Shanghai Composite Index closed at 3965.28, up 0.04%, while the Shenzhen Component Index closed at 13537.1, down 0.49% [1] Top Performers - Meihao Medical (301363) saw a closing price of 25.04, with an increase of 8.30% and a trading volume of 197,100 shares, totaling a transaction value of 482 million yuan [1] - Mailande (688273) closed at 41.73, up 8.22%, with a trading volume of 55,200 shares and a transaction value of 227 million yuan [1] - Kangzhong Medical (688607) closed at 45.80, up 7.23%, with a trading volume of 40,200 shares and a transaction value of 180 million yuan [1] Underperformers - Huakang Clean (301235) closed at 39.21, down 8.54%, with a trading volume of 123,300 shares and a transaction value of 488 million yuan [2] - C Jianxin (688805) closed at 47.16, down 7.26%, with a trading volume of 89,000 shares and a transaction value of 426 million yuan [2] - Furuim Medical (300049) closed at 71.93, down 4.20%, with a trading volume of 66,800 shares and a transaction value of 485 million yuan [2] Capital Flow - The medical device sector saw a net outflow of 565 million yuan from institutional investors, while retail investors experienced a net inflow of 328 million yuan [2] - The overall capital flow indicates a mixed sentiment, with institutional investors pulling back while retail investors are more active [2] Individual Stock Capital Flow - Meihao Medical (301363) had a net outflow of 54.30 million yuan from institutional investors, with retail investors also showing a net outflow of 0.76 million yuan [3] - Jigaofazhan (600807) experienced a net inflow of 44.75 million yuan from institutional investors, while retail investors had a net outflow of 61.29 million yuan [3] - Kangzhong Medical (688626) saw a net inflow of 44.26 million yuan from institutional investors, with retail investors showing a slight net outflow [3]

市场迷雾重重，还在为抓不住市场热点而焦虑？《掘金板块牛熊》帮你精准把握风格切换信号，带领你 看懂热钱的情绪周期。 每个交易日午间解密当天盘面热点的核心逻辑，《掘金板块牛熊》让你踩准市 场节奏，财富增值不迷路！ 【今日早盘观察】 ①牛榜 - "塑料中的黄金"PEEK材料概念走强！恒勃股份"20cm"涨停,超捷股份、光威复材、南京聚 隆、华密新材、双一科技、富恒新材等跟涨。PEEK材料牛在哪？产业链的核心股有哪些？ ②牛榜 - 脑机接口概念震荡走强！翔宇医疗涨超10%，倍益康、创新医疗、三博脑科、美好医疗、 博拓生物跟涨。脑机接口迎确定性关口，会有下一只翻倍股吗？ ③熊榜 - 锂电池板块震荡调整！锂矿、电解液方向领跌，欣旺达、宏源药业跌超10%，多氟多、天 华新能、大中矿业、海科新源、清水源均跌超7%。锂电板块怎么看？ 点击付费阅读，解密今日盘面热点的核心逻辑！ 前言 ...

今日上午，沪指、创业板指走势分化，截至上午收盘，沪指上涨0.31%，报3975.92点；深成指上涨0.03%，报13607.39点；创业板指下跌0.32%，报3233.53 点；科创50指数上涨0.91%，报1358.01点；北证50指数上涨0.11%，报1464.70点。 | G = 999999 上证指数 | | | --- | --- | | | 117.017. | | | 169.017 | | A股成交 | 5879.80 乙 | | B 股员 | 0.51 乙 | | 国债成 | 8797.87 乙 | | 是金成交 | 1413.99 Z | | 最新指数 | 3975.92 | | | 3964.65 | | | 3963.68 | | | 12.24 | | 指数据 | 0.31% | | 振幅 | 24.85/0.63% | | | 5882.45 Z | | | 36316.57 | 资金面上，央行今日开展4823亿元7天逆回购操作，操作利率为1.4%，与此前持平。因今日有673亿元7天期逆回购到期，实现净投放4150亿元。 消息面，在《中共中央关于制定国民经济和社会发展第十五个五年规 ...

Group 1 - The A-share market's brain-computer interface sector experienced a collective surge, with Xiangyu Medical rising over 9%, Sanbo Brain Science, Meihao Medical, Mylande, and Innovation Medical increasing over 6%, and Xilinmen, Pulite, and Botuo Bio rising over 5% [1] - The Fifth Frontier of Brain Science and Industry Conference and the 2025 Shenzhen Brain-Computer Interface Expo commenced on December 28, marking a significant event in the sector [1] - The "Guangdong-Hong Kong-Macao Greater Bay Area Brain Science and Central Nervous System Disease AI Innovation Alliance" was officially launched, indicating a collaborative effort to advance brain science and technology [1]

Summary of the Conference Call for Meihao Medical Company Overview - Meihao Medical has a solid business foundation in home respiratory machine components, cochlear implant components, and diabetes devices, particularly excelling in liquid silicone production and mold development, which supports its growth strategy [2][3] Industry Insights - The global home respiratory machine market is primarily dominated by ResMed, with Meihao Medical benefiting as an upstream supplier from ResMed's growth [2][8] - The home respiratory machine market is projected to reach USD 5-5.6 billion by 2025, with a compound annual growth rate (CAGR) of 10%-15% driven by increasing patient numbers and improved diagnosis rates [6][7] Financial Performance - From 2018 to 2024, Meihao Medical's revenue is expected to grow at a CAGR of approximately 18%, while net profit attributable to the parent company is projected to grow at about 8% [2][5] - As of Q3 2025, the company's gross margin and net profit have returned to historical averages, indicating potential for further improvement in profitability [5] Growth Strategies - Meihao Medical is actively expanding into overseas markets, particularly in the US, Europe, and Southeast Asia, where demand is strong. The overseas revenue growth rate remains high, and its share is continuously increasing [2][3] - The company is focusing on innovation and technology, with plans to launch new diabetes-related devices, including insulin pens and continuous glucose monitoring systems (CGM), expected to contribute to revenue in 2025 and see significant growth in 2026 [11][12] Competitive Advantages - The company's competitive edge lies in its core capabilities within the upstream supply chain, particularly in home respiratory machine components and cochlear implants. Its strong relationships with major overseas clients bolster its market position [3][4] - Meihao Medical's components account for approximately 20%-30% of ResMed's overall assembly costs, highlighting its importance as a supplier [9] Emerging Markets - The CGM market is rapidly growing, with domestic manufacturers experiencing over 50% annual growth since 2022. In contrast, CGM penetration in China is still low compared to Western countries, indicating significant growth potential [12] - Meihao Medical is also exploring cutting-edge technologies such as brain-machine interfaces and humanoid robots, leveraging its existing manufacturing capabilities in cochlear implants [13] Future Outlook - The company is expected to maintain a growth rate of 10%-15% from its core business, with new ventures potentially adding an additional 10% growth. Overall, future growth could reach 20%-25% [14] - The stock is currently valued at approximately 25 times earnings, with a target net profit of around RMB 540 million, leading to a "buy" recommendation for investors [14]

脑机接口板块大涨，建议加强重视十五五规划医疗科技方 向 20251225 摘要 中国在脑机接口领域处于全球相对领先地位。中国拥有大量医院和病人资源， 积极推动先进疗法的临床试验。此外，中国在医疗器械制造方面积累了丰富经 验，有望实现厚积薄发。目前，中国有许多团队从事脑机接口研究，数量甚至 可能超过美国。未来，中国有望涌现出具有全球竞争力的脑机接口公司，并逐 步走向国际市场。 目前有哪些公司在布局脑机接口领域？ 在上游零部件供应方面，美好医疗等公司为脑机接口企业提供代工服务。在康 复医疗器械领域，公司如翔宇医疗、迈兰德、韦斯和诚益通等都在积极布局。 此外，下游医院如三博脑科也非常重视这一方向。在非侵入式脑机接口方面， 强脑科技等公司备受关注。一级市场中，如博瑞康等公司也被寄予厚望，有望 通过上市形成更强的板块效应。 明年（2026 年）可以期待哪些政策支持？ 中国脑机接口领域发展迅速，受益于庞大的医院和病人资源以及医疗器 械制造经验，涌现出众多研究团队，数量或超美国，未来有望出现具全 球竞争力的公司。 政策支持力度加大，预计 2026 年将迎来国家顶层设计、资金支持以及 药监局绿色通道等多方面政策利好，加速产品 ...

近5日融资融券数据一览见下表： 该股主要指标及行业内排名如下： 证券之星消息，截至2025年12月25日收盘，美好医疗(301363)报收于23.65元，上涨4.19%，换手率 4.56%，成交量17.01万手，成交额4.02亿元。 12月25日的资金流向数据方面，主力资金净流入2331.96万元，占总成交额5.8%，游资资金净流出 4346.96万元，占总成交额10.82%，散户资金净流入2015.0万元，占总成交额5.01%。 近5日资金流向一览见下表： 美好医疗融资融券信息显示，融资方面，当日融资买入3367.36万元，融资偿还2344.93万元，融资净买 入1022.44万元。融券方面，融券卖出4400.0股，融券偿还1100.0股，融券余量4.25万股，融券余额 100.47万元。融资融券余额1.45亿元。 美好医疗2025年三季报显示，前三季度公司主营收入11.94亿元，同比上升3.28%；归母净利润2.08亿 元，同比下降19.25%；扣非净利润2.03亿元，同比下降17.85%；其中2025年第三季度，公司单季度主营 收入4.62亿元，同比上升2.56%；单季度归母净利润9390.02万元，同 ...

Core Viewpoint - The medical device sector is experiencing a rebound, with significant inflows into the medical device ETF fund, indicating positive market sentiment and potential investment opportunities [1][3]. Group 1: Market Performance - The Shanghai Composite Index recorded a seven-day rise, with the medical device ETF fund (159797) increasing by 1.58% for two consecutive days [1]. - The medical device ETF fund has seen a net inflow for six consecutive days, accumulating over 31 million yuan in the last ten days [1]. - Most component stocks of the medical device ETF fund closed in the green, with notable gains from companies such as SINO Medical (up over 14%) and Xiangyu Medical (up over 6%) [3]. Group 2: Procurement Policy - The National Organization for High-Value Medical Consumables announced a centralized procurement document for drug-coated balloons and urological intervention consumables, with submission deadlines set for January 13, 2026 [3]. - The procurement cycle will last until December 31, 2028, indicating a long-term commitment to cost control in the medical device sector [3]. Group 3: Industry Outlook - The outlook for 2026 suggests a focus on innovation and international markets, with domestic demand expected to recover gradually [6]. - The medical device sector is anticipated to benefit from policy support and the increasing market share of leading companies, despite current pressures on domestic demand [6]. - The strategy for 2026 will emphasize overseas expansion and innovative products, which are expected to sustain profit margins amid price declines in traditional business areas [6]. Group 4: Specific Sector Insights - The medical device sector's growth will increasingly rely on domestic manufacturers' technological advancements and expansion into rural healthcare markets [7]. - The high-value consumables market is expected to see continued policy-driven changes, with a focus on optimizing bidding mechanisms and expanding product categories [7]. - The low-value consumables segment is adapting to global trade changes by accelerating overseas production to regain market share lost due to tariffs [8]. Group 5: Future Trends - The in-vitro diagnostics market is experiencing a shift towards domestic brands, which are gaining market share through competitive pricing and distribution advantages [8]. - The home medical device sector is prioritizing internationalization, with leading companies pursuing acquisitions and product registrations abroad to enhance growth prospects [8].

Market Overview - The medical device sector increased by 1.35% on December 25, with Sainuo Medical leading the gains [1] - The Shanghai Composite Index closed at 3959.62, up 0.47%, while the Shenzhen Component Index closed at 13531.41, up 0.33% [1] Top Performers - Sainuo Medical (688108) closed at 20.43, up 14.90%, with a trading volume of 609,800 shares and a transaction value of 1.22 billion [1] - Jinhao Medical (920925) closed at 33.03, up 12.81%, with a trading volume of 38,400 shares [1] - Mailland (688273) closed at 40.38, up 12.07%, with a trading volume of 54,800 shares [1] - Tianchen Medical (688013) closed at 52.94, up 11.10%, with a trading volume of 31,200 shares [1] - Xiangyu Medical (688626) closed at 57.47, up 6.80%, with a trading volume of 53,400 shares [1] Underperformers - C Jianxin (688805) closed at 53.31, down 8.28%, with a trading volume of 142,100 shares and a transaction value of 754 million [2] - Tianyi Medical (301097) closed at 51.89, down 5.43%, with a trading volume of 18,800 shares [2] - Hualan Co. (301093) closed at 49.54, down 2.75%, with a trading volume of 39,000 shares [2] Capital Flow - The medical device sector saw a net inflow of 137 million from institutional investors, while retail investors experienced a net inflow of 65.58 million [2] - The sector's main funds saw a net outflow of 203 million from speculative funds [2] Individual Stock Capital Flow - Sainuo Medical had a net inflow of 117 million from main funds, but a net outflow of 98.09 million from retail investors [3] - Zhend Medical (603301) had a net inflow of 85.32 million from main funds, with a net outflow of 76.17 million from retail investors [3] - Huakang Clean (301235) had a net inflow of 65.37 million from main funds, with a net outflow of 64.32 million from retail investors [3]